Article Text

Download PDFPDF
Sarcoid-like reaction: a unique response to immunotherapy in malignant melanoma
  1. Taha Khalid1,
  2. Asma Patel1,
  3. Alina Ahmed2 and
  4. Ala Yousif1
  1. 1Oncology, Sligo University Hospital, Sligo, Ireland
  2. 2Medicine, Kingsbridge Private Hospital, Sligo, Ireland
  1. Correspondence to Dr Taha Khalid; tahakhalid{at}outlook.ie

Abstract

In recent years, immunotherapy has revolutionised the treatment landscape for oncology patients with improved survival rates in cancers which previously had a dismissal prognosis. These agents target specific pathways of inhibition such as programmed cell death -1 (PD-1), PD ligand-1 and cytotoxic T-lymphocyte-associated antigen 4 resulting in stimulation of T cell activity. This results in enabling an individual’s own immune system to fight against cancer, a different modality of treatment when compared with traditional chemotherapy. While attacking the tumour cells, there is an increased chance of host tissue immune reactions.

We report a case of a patient who received immunotherapy for metastatic malignant melanoma. During the course of the treatment, development of a sarcoid-like reaction was histologically confirmed in the mediastinal lymph nodes. The patient had no respiratory symptoms and continued on the immunotherapy treatment with good clinical and radiological response.

  • skin cancer
  • immunology
  • respiratory system

Statistics from Altmetric.com

Footnotes

  • Correction notice This article has been corrected since it was published Online. The author's name has been corrected from "Asma Patil" to "Asma Patel". Also, "Darrell Martin" has been included in the acknowledgement section.

  • Contributors TK: literature research and formatting for this case report. AP: consented the patient and helped with the literature research. AA: assisted with the formatting and literature research. AY: was the mentor and supervisor for the case report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.